Hudson Bay Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Hudson Bay Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4M	Sell	400,000 -90,369	-18%	-$817K	0.01%	629
2026 Q1	$4.67M	Sell	490,369 -527,005	-52%	-$4.09M	0.02%	531
2025 Q4	$7.94M	Buy	+1,017,374	New	+$7.35M	0.03%	386
2025 Q3	–	Sell	-304,772	Closed	-$2.73M	–	1263
2025 Q2	$2.73M	Sell	304,772 -193,907	-39%	-$1.81M	0.01%	709
2025 Q1	$3.74M	Buy	+498,679	New	+$4.02M	0.01%	678
2024 Q3	–	Sell	-180,000	Closed	-$1.11M	–	866
2024 Q2	$1.11M	Sell	180,000 -120,000	-40%	-$662K	0.01%	596
2024 Q1	$1.52M	Buy	300,000 +170,000	+131%	+$956K	0.01%	500
2023 Q4	$779K	Buy	130,000 +65,000	+100%	+$377K	﹤0.01%	538
2023 Q3	$460K	Buy	65,000 +300	+0.5%	+$2.15K	﹤0.01%	604
2023 Q2	$455K	Buy	64,700 +22,200	+52%	+$178K	﹤0.01%	633
2023 Q1	$354K	Buy	42,500 +17,500	+70%	+$168K	﹤0.01%	636
2022 Q4	$287K	Buy	+25,000	New	+$312K	﹤0.01%	738
2019 Q2	–	Sell	-140,000	Closed	-$1.14M	–	437
2019 Q1	$1.14M	Buy	140,000 +10,000	+8%	+$85.6K	0.01%	540
2018 Q4	$1.05M	Sell	130,000 -90,000	-41%	-$700K	0.01%	629
2018 Q3	$1.68M	Sell	220,000 -80,000	-27%	-$537K	0.02%	497
2018 Q2	$1.72M	Sell	300,000 -260,000	-46%	-$1.43M	0.02%	545
2018 Q1	$2.67M	Buy	+560,000	New	+$2.88M	0.06%	384

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Hudson Bay Capital Management's BCRX Position: Q2 2026 in Review

Hudson Bay Capital Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 18% in Q2 2026, selling an estimated $817K and leaving 400,000 shares worth $4M. The position accounts for 0.01% of the portfolio, ranked #629.

Hudson Bay Capital Management first reported a position in BCRX in Q1 2018 and has held it in 17 quarters since. The position peaked at $7.94M in Q4 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Hudson Bay Capital Management held 400,000 shares of BioCryst Pharmaceuticals worth $4M as of Q2 2026.
Hudson Bay Capital Management sold 90,369 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $817K.
BioCryst Pharmaceuticals made up 0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #629 holding.
Hudson Bay Capital Management first reported a position in BioCryst Pharmaceuticals in Q1 2018 and has held it in 17 quarters since.
Hudson Bay Capital Management's BioCryst Pharmaceuticals position peaked at $7.94M in Q4 2025.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.